HM
Therapeutic Areas
Axsome Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Auvelity (AXS-05) | Major Depressive Disorder | Approved |
| Sunosi (Solriamfetol) | Excessive Daytime Sleepiness | Approved |
| Symbravo | Migraine | Approved |
| AXS-05 | Alzheimer's Disease Agitation | Phase 3 |
| AXS-12 | Narcolepsy with Cataplexy | Phase 3 |
| AXS-14 | Fibromyalgia | Phase 3 |
| Solriamfetol (CLARITY Trial) | Major Depressive Disorder with Excessive Daytime Sleepiness | Phase 3 |
Leadership Team at Axsome Therapeutics
DH
Dr. Herriot Tabuteau
Chief Executive Officer and Founder
NP
Nick Pizzie
Chief Financial Officer
MJ
Mark Jacobson
Chief Operating Officer
AM
Ari Maizel
Chief Commercial Officer
DM
Dr. Mark Coleman
Director, Board of Directors
DR
Dr. Roger Jeffs
Director, Board of Directors
DS
Dr. Susan Mahony
Director, Board of Directors